I 
117TH CONGRESS 
2D SESSION 
H. R. 6374 
To implement the recommendations of the Inspector General of the Depart-
ment of Defense with respect to mitigation of foreign suppliers in the 
pharmaceutical supply chain of the Department of Defense. 
IN THE HOUSE OF REPRESENTATIVES 
JANUARY 12, 2022 
Ms. HOULAHAN (for herself and Mr. MEIJER) introduced the following bill; 
which was referred to the Committee on Armed Services 
A BILL 
To implement the recommendations of the Inspector General 
of the Department of Defense with respect to mitigation 
of foreign suppliers in the pharmaceutical supply chain 
of the Department of Defense. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Strengthening Supply 
Chains for Servicemembers and Security Act’’. 
VerDate Sep 11 2014 
00:29 Jan 14, 2022
Jkt 029200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H6374.IH
H6374
pbinns on DSKJLVW7X2PROD with BILLS
SEC. 2. RISK MANAGEMENT FOR DEPARTMENT OF DE-
FENSE SUPPLY CHAINS. 
(a) RISK MANAGEMENT FOR ALL DEPARTMENT OF 
DEFENSE SUPPLY CHAINS.—Not later than 180 days 
after the date of the enactment of this Act, the Under 
Secretary of Defense for Acquisition and Sustainment 
shall— 
(1) develop and issue implementing guidance 
for risk management for Department of Defense 
supply chains for materiel for the Department, in-
cluding pharmaceuticals; 
(2) identify, in coordination with the Commis-
sioner of Food and Drugs, supply chain information 
gaps regarding reliance on foreign suppliers of 
drugs, including active pharmaceutical ingredients 
and final drug products; and 
(3) submit to Congress a report regarding— 
(A) existing information streams, if any, 
that may be used to assess the reliance by the 
Department of Defense on high-risk foreign 
suppliers of drugs; 
(B) vulnerabilities in the drug supply 
chains of the Department of Defense; and 
(C) any recommendations to address— 
(i) information gaps identified under 
paragraph (2); and 
VerDate Sep 11 2014 
00:29 Jan 14, 2022
Jkt 029200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H6374.IH
H6374
pbinns on DSKJLVW7X2PROD with BILLS
(ii) any risks related to such reliance 
on foreign suppliers. 
(b) RISK MANAGEMENT FOR DEPARTMENT OF DE-
FENSE PHARMACEUTICAL SUPPLY CHAIN.—The Director 
of the Defense Health Agency shall— 
(1) not later than one year after the issuance 
of the guidance required by subsection (a)(1), de-
velop and publish implementing guidance for risk 
management for the Department of Defense supply 
chain for pharmaceuticals; and 
(2) establish a working group— 
(A) to assess risks to the pharmaceutical 
supply chain; 
(B) to identify the pharmaceuticals most 
critical to beneficiary care at military treatment 
facilities; and 
(C) to establish policies for allocating 
scarce pharmaceutical resources in case of a 
supply disruption. 
(c) RESPONSIVENESS TESTING OF DEFENSE LOGIS-
TICS AGENCY PHARMACEUTICAL CONTRACTS.—The Di-
rector of the Defense Logistics Agency shall modify De-
fense 
Logistics 
Agency 
Instructions 
5025.03 
and 
3110.01— 
VerDate Sep 11 2014 
00:29 Jan 14, 2022
Jkt 029200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H6374.IH
H6374
pbinns on DSKJLVW7X2PROD with BILLS
(1) to require Defense Logistics Agency Troop 
Support to coordinate annually with customers in 
the military departments to conduct responsiveness 
testing of the Defense Logistics Agency’s contin-
gency contracts for pharmaceuticals; and 
(2) to include the results of that testing, as re-
ported by customers in the military departments, in 
the annual reports of the Warstopper Program. 
Æ 
VerDate Sep 11 2014 
00:29 Jan 14, 2022
Jkt 029200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\H6374.IH
H6374
pbinns on DSKJLVW7X2PROD with BILLS